HANGER, INC. - Quarter Report: 2012 June (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2012
OR
o |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 1-10670
HANGER, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
84-0904275 |
(State or other jurisdiction of |
|
(IRS Employer Identification No.) |
incorporation or organization) |
|
|
10910 Domain Drive, Suite 300, Austin, TX |
|
78758 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (512) 777-3800
Formerly Hanger Orthopedic Group, Inc.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one).
Large accelerated filer x |
|
Accelerated filer o |
|
|
|
Non-accelerated filer o |
|
Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. Yes o No x
As of July 27, 2012 34,199,023 shares of common stock, $.01 par value per share, were outstanding.
HANGER, INC.
|
|
Page No. |
|
|
|
Part I. |
FINANCIAL INFORMATION |
|
|
|
|
Item 1. |
Consolidated Financial Statements (unaudited) |
|
|
|
|
|
Consolidated Balance Sheets June 30, 2012 and December 31, 2011 |
1 |
|
|
|
|
3 | |
|
|
|
|
Consolidated Statements of Cash Flows for the Six Months ended June 30, 2012 and 2011 |
4 |
|
|
|
|
5 | |
|
|
|
Managements Discussion and Analysis of Financial Condition and Results of Operations |
17 | |
|
|
|
30 | ||
|
|
|
30 | ||
|
|
|
| ||
|
|
|
30 | ||
|
|
|
33 | ||
|
|
|
34 |
HANGER, INC.
(Dollars in thousands)
(Unaudited)
|
|
June 30, |
|
December 31, |
| ||
|
|
2012 |
|
2011 |
| ||
|
|
|
|
|
| ||
ASSETS |
|
|
|
|
| ||
|
|
|
|
|
| ||
CURRENT ASSETS |
|
|
|
|
| ||
Cash and cash equivalents |
|
$ |
41,613 |
|
$ |
42,896 |
|
Restricted cash |
|
3,120 |
|
|
| ||
Accounts receivable, less allowance for doubtful accounts of $24,382 and $22,028 in 2012 and 2011, respectively |
|
142,551 |
|
138,826 |
| ||
Inventories |
|
124,815 |
|
114,086 |
| ||
Prepaid expenses, other assets, and income taxes receivable |
|
18,273 |
|
17,015 |
| ||
Deferred income taxes |
|
20,652 |
|
20,648 |
| ||
Total current assets |
|
351,024 |
|
333,471 |
| ||
|
|
|
|
|
| ||
PROPERTY, PLANT AND EQUIPMENT |
|
|
|
|
| ||
Land |
|
794 |
|
794 |
| ||
Buildings |
|
7,302 |
|
4,400 |
| ||
Furniture and fixtures |
|
17,991 |
|
17,281 |
| ||
Machinery and equipment |
|
58,264 |
|
56,137 |
| ||
Equipment leased to third parties under operating leases |
|
34,314 |
|
33,830 |
| ||
Leasehold improvements |
|
67,801 |
|
65,245 |
| ||
Computer and software |
|
91,107 |
|
81,775 |
| ||
Total property, plant and equipment, gross |
|
277,573 |
|
259,462 |
| ||
Less accumulated depreciation |
|
168,262 |
|
154,690 |
| ||
Total property, plant and equipment, net |
|
109,311 |
|
104,772 |
| ||
|
|
|
|
|
| ||
INTANGIBLE ASSETS |
|
|
|
|
| ||
Goodwill |
|
615,732 |
|
609,484 |
| ||
Patents and other intangible assets, net |
|
54,732 |
|
54,894 |
| ||
Total intangible assets, net |
|
670,464 |
|
664,378 |
| ||
|
|
|
|
|
| ||
OTHER ASSETS |
|
|
|
|
| ||
Debt issuance costs, net |
|
15,759 |
|
17,485 |
| ||
Other assets |
|
8,623 |
|
8,394 |
| ||
Total other assets |
|
24,382 |
|
25,879 |
| ||
|
|
|
|
|
| ||
TOTAL ASSETS |
|
$ |
1,155,181 |
|
$ |
1,128,500 |
|
The accompanying notes are an integral part of the consolidated financial statements.
HANGER, INC.
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands)
(Unaudited)
|
|
June 30, |
|
December 31, |
| ||
|
|
2012 |
|
2011 |
| ||
|
|
|
|
|
| ||
LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
| ||
|
|
|
|
|
| ||
CURRENT LIABILITIES |
|
|
|
|
| ||
Current portion of long-term debt |
|
$ |
6,115 |
|
$ |
8,065 |
|
Accounts payable |
|
29,116 |
|
26,561 |
| ||
Accrued expenses |
|
22,915 |
|
18,247 |
| ||
Accrued interest payable |
|
3,034 |
|
3,040 |
| ||
Accrued compensation related costs |
|
23,990 |
|
35,829 |
| ||
Total current liabilities |
|
85,170 |
|
91,742 |
| ||
|
|
|
|
|
| ||
LONG-TERM LIABILITIES |
|
|
|
|
| ||
Long-term debt, less current portion |
|
498,311 |
|
499,968 |
| ||
Deferred income taxes |
|
74,257 |
|
74,309 |
| ||
Other liabilities |
|
37,025 |
|
32,818 |
| ||
Total liabilities |
|
694,763 |
|
698,837 |
| ||
|
|
|
|
|
| ||
COMMITMENTS AND CONTINGENCIES (Note H) |
|
|
|
|
| ||
|
|
|
|
|
| ||
SHAREHOLDERS EQUITY |
|
|
|
|
| ||
Common stock, $.01 par value; 60,000,000 shares authorized, 35,504,100 and 35,127,230 shares issued and outstanding at 2012 and 2011, respectively |
|
355 |
|
351 |
| ||
Additional paid-in capital |
|
274,345 |
|
268,535 |
| ||
Accumulated other comprehensive loss |
|
(1,185 |
) |
(1,185 |
) | ||
Retained earnings |
|
187,559 |
|
162,618 |
| ||
|
|
461,074 |
|
430,319 |
| ||
Treasury stock at cost (141,154 shares) |
|
(656 |
) |
(656 |
) | ||
Total shareholders equity |
|
460,418 |
|
429,663 |
| ||
|
|
|
|
|
| ||
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY |
|
$ |
1,155,181 |
|
$ |
1,128,500 |
|
The accompanying notes are an integral part of the consolidated financial statements.
HANGER, INC.
CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
For the Three and Six Months Ended June 30,
(Dollars in thousands, except share and per share amounts)
(Unaudited)
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
2012 |
|
2011 |
|
2012 |
|
2011 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Net sales |
|
$ |
251,754 |
|
$ |
234,751 |
|
$ |
469,846 |
|
$ |
435,190 |
|
Cost of goods sold - materials |
|
72,899 |
|
68,514 |
|
136,998 |
|
126,622 |
| ||||
Personnel costs |
|
83,435 |
|
81,014 |
|
167,054 |
|
159,903 |
| ||||
Other operating expenses |
|
51,256 |
|
44,603 |
|
93,389 |
|
81,993 |
| ||||
Relocation expenses |
|
|
|
42 |
|
|
|
417 |
| ||||
Depreciation and amortization |
|
8,438 |
|
7,696 |
|
16,723 |
|
14,988 |
| ||||
Income from operations |
|
35,726 |
|
32,882 |
|
55,682 |
|
51,267 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Interest expense |
|
7,684 |
|
7,791 |
|
15,461 |
|
16,170 |
| ||||
Income before taxes |
|
28,042 |
|
25,091 |
|
40,221 |
|
35,097 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Provision for income taxes |
|
10,656 |
|
9,660 |
|
15,280 |
|
13,453 |
| ||||
Net income |
|
$ |
17,386 |
|
$ |
15,431 |
|
$ |
24,941 |
|
$ |
21,644 |
|
|
|
|
|
|
|
|
|
|
| ||||
Other comprehensive income |
|
|
|
|
|
|
|
|
| ||||
Comprehensive income |
|
$ |
17,386 |
|
$ |
15,431 |
|
$ |
24,941 |
|
$ |
21,644 |
|
|
|
|
|
|
|
|
|
|
| ||||
Basic Per Common Share Data |
|
|
|
|
|
|
|
|
| ||||
Net income |
|
$ |
0.51 |
|
$ |
0.46 |
|
$ |
0.73 |
|
$ |
0.65 |
|
Shares used to compute basic per common share amounts |
|
34,268,941 |
|
33,499,268 |
|
34,110,820 |
|
33,429,502 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Diluted Per Common Share Data |
|
|
|
|
|
|
|
|
| ||||
Net income |
|
$ |
0.50 |
|
$ |
0.45 |
|
$ |
0.72 |
|
$ |
0.63 |
|
Shares used to compute diluted per common share amounts |
|
34,720,489 |
|
34,365,395 |
|
34,637,769 |
|
34,284,513 |
|
The accompanying notes are an integral part of the consolidated financial statements.
HANGER, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Six Months Ended June 30,
(Dollars in thousands)
(Unaudited)
|
|
2012 |
|
2011 |
| ||
|
|
|
|
|
| ||
Cash flows from operating activities: |
|
|
|
|
| ||
Net income |
|
$ |
24,941 |
|
$ |
21,644 |
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
|
|
|
|
| ||
Loss (gain) on disposal of assets |
|
1 |
|
(45 |
) | ||
Reduction of seller notes and earnouts |
|
(870 |
) |
(281 |
) | ||
Provision for bad debts |
|
12,925 |
|
10,891 |
| ||
Provision for deferred income taxes |
|
|
|
(343 |
) | ||
Depreciation and amortization |
|
16,723 |
|
14,988 |
| ||
Amortization of debt issuance costs |
|
1,726 |
|
1,607 |
| ||
Compensation expense on restricted stock |
|
4,014 |
|
3,874 |
| ||
Excess tax benefit from stock-based compensation |
|
(448 |
) |
(1,095 |
) | ||
Changes in operating assets and liabilities, net of effects of acquired companies: |
|
|
|
|
| ||
Accounts receivable |
|
(16,190 |
) |
(12,779 |
) | ||
Inventories |
|
(10,272 |
) |
(4,181 |
) | ||
Prepaid expenses, other current assets, and income taxes |
|
1,915 |
|
5,021 |
| ||
Accounts payable |
|
2,327 |
|
(7,583 |
) | ||
Accrued expenses and accrued interest payable |
|
501 |
|
(1,854 |
) | ||
Accrued compensation related costs |
|
(12,562 |
) |
(19,332 |
) | ||
Other |
|
2,270 |
|
106 |
| ||
Net cash provided by operating activities |
|
27,001 |
|
10,638 |
| ||
|
|
|
|
|
| ||
Cash flows from investing activities: |
|
|
|
|
| ||
Purchase of property, plant and equipment (net of acquisitions) |
|
(14,907 |
) |
(13,630 |
) | ||
Purchase of equipment leased to third parties under operating leases |
|
(1,063 |
) |
(1,639 |
) | ||
Acquisitions and contingent purchase price (net of cash acquired) |
|
(6,395 |
) |
(6,064 |
) | ||
Proceeds from sale of property, plant and equipment |
|
|
|
94 |
| ||
Restricted cash |
|
(3,120 |
) |
|
| ||
Net cash used in investing activities |
|
(25,485 |
) |
(21,239 |
) | ||
|
|
|
|
|
| ||
Cash flows from financing activities: |
|
|
|
|
| ||
Borrowings under revolving credit agreement |
|
|
|
10,000 |
| ||
Repayment under revolving credit agreement |
|
|
|
(10,000 |
) | ||
Repayment of term loan |
|
(2,200 |
) |
(1,500 |
) | ||
Repayment of long-term debt |
|
(2,451 |
) |
(2,119 |
) | ||
Repayment of capital lease obligations |
|
(168 |
) |
|
| ||
Deferred financing costs |
|
|
|
(4,230 |
) | ||
Excess tax benefit from stock-based compensation |
|
448 |
|
1,095 |
| ||
Proceeds from issuance of common stock |
|
1,572 |
|
573 |
| ||
Net cash used in financing activities |
|
(2,799 |
) |
(6,181 |
) | ||
|
|
|
|
|
| ||
Decrease in cash and cash equivalents |
|
(1,283 |
) |
(16,782 |
) | ||
Cash and cash equivalents, at beginning of period |
|
42,896 |
|
36,308 |
| ||
Cash and cash equivalents, at end of period |
|
$ |
41,613 |
|
$ |
19,526 |
|
The accompanying notes are an integral part of the consolidated financial statements.
HANGER, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE A BASIS OF PRESENTATION
The unaudited interim consolidated financial statements as of June 30, 2012, and for the three and six months ended June 30, 2012 and 2011 have been prepared by Hanger, Inc. (the Company) pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC) for interim financial reporting. These consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) considered necessary for a fair statement of the Companys financial position, results of operations and cash flows for such periods. The year-end consolidated data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (GAAP). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The results of operations for the three and six months ended June 30, 2012 are not necessarily indicative of the results to be expected for the full fiscal year.
These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company and notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the SEC.
NOTE B SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the accompanying financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. At various times throughout the year, the Company maintains cash balances in excess of Federal Deposit Insurance Corporation limits.
Restricted Cash
Restricted cash has statutory or contractual restrictions that prevent it from being used in the Companys operations. The Company agreed to restrict $3.1 million of cash to eliminate letters of credit obligations used as collateral under the revolving credit facility.
Inventories
Inventories, which consist principally of raw materials, work in process and finished goods, are stated at the lower of cost or market using the first-in, first-out method. For its Patient-Care Services segment, the Company calculates cost of goods soldmaterials in accordance with the gross profit method for all reporting periods.
NOTE B SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
The Company bases the estimates used in applying the gross profit method on the actual results of the most recently completed fiscal year and other factors, such as a change in the sales mix or changes in the trend of purchases. Cost of goods soldmaterials during the interim periods are reconciled and adjusted when the annual physical inventory is taken. The Company treats these adjustments as changes in accounting estimates.
Fair Value of Financial Instruments
The carrying value of the Companys short-term financial instruments, such as receivables and payables, approximate their fair values based on the short-term maturities of these instruments. The carrying value of the Companys long-term debt, excluding the Senior Notes, approximates fair value based on rates currently available to the Company for debt with similar terms and remaining maturities (level 2). The fair value of the Senior Notes, based on quoted market prices (level 1), as of June 30, 2012 was $206.0 million, as compared to the carrying value of $200.0 million as of that date.
Revenue Recognition
Revenues in the Companys patient-care centers are derived from the sale of O&P devices and the maintenance and repair of existing devices and are recorded net of all contractual adjustments and discounts. The sale of O&P devices includes the design, fabrication, assembly, fitting and delivery of a wide range of braces, limbs and other devices. Revenues from the sale of these devices are recorded when (i) acceptance by and delivery to the patient has occurred; (ii) persuasive evidence of an arrangement exists and there are no further obligations to the patient; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Revenues from maintenance and repairs are recognized when the service is provided. Revenues on the sale of O&P devices to customers by the Distribution segment are recorded upon the shipment of products, in accordance with the terms of the invoice, net of merchandise returns received and the amount established for anticipated returns. Discounted sales are recorded at net realizable value. Revenues in the Therapeutic Solutions segment are primarily derived from leasing rehabilitation technology combined with clinical therapy programs and education and training. The revenue is recorded on a monthly basis according to terms of the contracts with our customers.
Certain accounts receivable may be uncollectible, even if properly pre-authorized and billed. Regardless of the balance, accounts receivable amounts are periodically evaluated to assess collectability. In addition to the actual bad debt expense recognized during collection activities, the Company estimates the amount of potential bad debt expense that may occur in the future. This estimate is based upon historical experience as well as a review of the receivable balances.
On a quarterly basis, the Company evaluates cash collections, accounts receivable balances and write-off activity to assess the adequacy of the allowance for doubtful accounts. Additionally, a company-wide evaluation of collectability of receivable balances older than 180 days is performed at least semi-annually, the results of which are used in the next allowance analysis. In these detailed reviews, the accounts net realizable value is estimated after considering the customers payment history, past efforts to collect on the balance and the outstanding balance, and a specific reserve is recorded if needed. From time to time, the Company may outsource the collection of such accounts to collection agencies after internal collection efforts are exhausted. In the cases when valid accounts receivable cannot be collected, the uncollectible account is written off to bad debt expense.
NOTE B SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Income Taxes
The Company recognizes deferred income tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income tax liabilities and assets are determined based on the difference between the financial statement and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes a valuation allowance on the deferred tax assets if it is more likely than not that the assets will not be realized in future years. Significant accounting judgment is required in determining the provision for income taxes and related accruals, deferred tax assets and liabilities. The Company believes that its tax positions are consistent with applicable tax law, but certain positions may be challenged by taxing authorities. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, the Company is subject to periodic audits and examinations by the Internal Revenue Service and other state and local taxing authorities. Although the Company believes that its estimates are reasonable, actual results could differ from these estimates.
Segment Information
The Company applies a management approach to disclosure of segment information. The management approach designates the internal organization that is used by management for making operating decisions and assessing performance as the basis of the Companys reportable segments. The description of the Companys reportable segments and the disclosure of segment information are presented in Note L.
NOTE C - SUPPLEMENTAL CASH FLOW FINANCIAL INFORMATION
The supplemental disclosure requirements for the statements of cash flows are as follows:
|
|
Six Months Ended |
| ||||
|
|
June 30, |
| ||||
(In thousands) |
|
2012 |
|
2011 |
| ||
|
|
(Unaudited) |
|
(Unaudited) |
| ||
Cash paid during the period for: |
|
|
|
|
| ||
Interest |
|
$ |
13,444 |
|
$ |
13,885 |
|
Income taxes (net of refunds) |
|
8,818 |
|
3,077 |
| ||
|
|
|
|
|
| ||
Non-cash financing and investing activities: |
|
|
|
|
| ||
Non-cash property, plant and equipment purchases |
|
615 |
|
218 |
| ||
Earnouts payable on acquisitions |
|
1,842 |
|
647 |
| ||
Issuance of notes in connection with acquistions |
|
1,250 |
|
1,100 |
| ||
Issuance of restricted shares of common stock |
|
5,478 |
|
12,963 |
| ||
NOTE D - GOODWILL
The Company determined that it has three reporting units with goodwill to be evaluated, which are the same as its reportable segments: (i) Patient-Care Services; (ii) Distribution; and (iii) Therapeutic Solutions. The Company completes its annual goodwill impairment analysis in October of each year. The fair value of the Companys reporting units is primarily determined based on the income approach and considers the market and cost approach.
NOTE D GOODWILL (CONTINUED)
The activity related to goodwill for the six months ended June 30, 2012 and 2011 is as follows:
|
|
Patient-Care Services |
|
|
|
Therapeutic |
|
|
| ||||||||||
|
|
|
|
Accumulated |
|
|
|
Distribution |
|
Solutions |
|
|
| ||||||
(In thousands) |
|
Goodwill |
|
Impairment Loss |
|
Net |
|
Goodwill |
|
Goodwill |
|
Total |
| ||||||
Balance at December 31, 2011 |
|
$ |
519,974 |
|
$ |
(45,808 |
) |
$ |
474,166 |
|
$ |
38,388 |
|
$ |
96,930 |
|
$ |
609,484 |
|
Additions due to acquisitions |
|
4,807 |
|
|
|
4,807 |
|
|
|
964 |
|
5,771 |
| ||||||
Additions due to contingent considerations |
|
477 |
|
|
|
477 |
|
|
|
|
|
477 |
| ||||||
Balance at June 30, 2012 (unaudited) |
|
$ |
525,258 |
|
$ |
(45,808 |
) |
$ |
479,450 |
|
$ |
38,388 |
|
$ |
97,894 |
|
$ |
615,732 |
|
|
|
Patient-Care Services |
|
|
|
Therapeutic |
|
|
| ||||||||||
|
|
|
|
Accumulated |
|
|
|
Distribution |
|
Solutions |
|
|
| ||||||
(In thousands) |
|
Goodwill |
|
Impairment Loss |
|
Net |
|
Goodwill |
|
Goodwill |
|
Total |
| ||||||
Balance at December 31, 2010 |
|
$ |
502,040 |
|
$ |
(45,808 |
) |
$ |
456,232 |
|
$ |
38,388 |
|
$ |
96,079 |
|
$ |
590,699 |
|
Additions due to acquisitions |
|
4,910 |
|
|
|
4,910 |
|
|
|
423 |
|
5,333 |
| ||||||
Additions due to contingent considerations |
|
741 |
|
|
|
741 |
|
|
|
|
|
741 |
| ||||||
Balance at June 30, 2011 (unaudited) |
|
$ |
507,691 |
|
$ |
(45,808 |
) |
$ |
461,883 |
|
$ |
38,388 |
|
$ |
96,502 |
|
$ |
596,773 |
|
NOTE E INVENTORIES
Inventories, which are recorded at the lower of cost or market using the first-in, first-out method, were as follows:
|
|
June 30, |
|
December 31, |
| ||
(In thousands) |
|
2012 |
|
2011 |
| ||
|
|
(Unaudited) |
|
(Unaudited) |
| ||
|
|
|
|
|
| ||
Raw materials |
|
$ |
39,627 |
|
$ |
39,121 |
|
Work-in-process |
|
56,636 |
|
45,735 |
| ||
Finished goods |
|
28,551 |
|
29,230 |
| ||
|
|
$ |
124,815 |
|
$ |
114,086 |
|
NOTE F ACQUISITIONS
During the six months ended June 30, 2012, the Company acquired five O&P companies, operating a total of eight patient-care centers. The aggregate purchase price for these O&P businesses was $8.6 million. Of this aggregate purchase price, $1.2 million consisted of promissory notes, $1.8 million is made up of contingent consideration payable within the next five years, and $5.6 million was paid in cash. Contingent consideration is reported as other liabilities on the Companys consolidated balance sheet. The Company recorded approximately $5.5 million of goodwill related to these acquisitions, and the expenses incurred related to this acquisition were insignificant and are included in other operating expenses. During the six months ended June 30, 2011, the Company acquired three O&P companies, operating a total of four patient care centers. The aggregate purchase price for these O&P businesses was $7.3 million. Of this aggregate purchase price, $1.1 million consisted of promissory notes and $0.9 million is made up of contingent consideration payable within the next two years and $5.3 million was paid in cash. The Company recorded approximately $4.9 million of goodwill related to these acquisitions and the expenses incurred related to these acquisitions were insignificant and are included in other operating expenses.
The results of operations for these acquisitions are included in the Companys results of operations from the date of acquisition. Pro forma results would not be materially different. The Company intends to make an election to treat the acquisitions in 2012 as asset acquisitions for tax purposes which will result in the goodwill being amortizable for tax purposes.
NOTE F ACQUISITIONS (CONTINUED)
In connection with contingent consideration agreements with acquisitions completed prior to adoption of the revised authoritative guidance effective for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008, the Company made payments of $0.5 million and $0.7 million during the six months ended June 30, 2012 and 2011, respectively. The Company has accounted for these amounts as additional purchase price, resulting in an increase in goodwill. In connection with contingent consideration agreements with acquisitions completed subsequent to adoption of revised authoritative guidance, the Company made payments of $0.8 million in the first six months of 2012 and $0.6 million in the same period 2011. The Company estimates that it may pay up to a total of $7.9 million related to contingent consideration provisions of acquisitions in future periods.
NOTE G LONG TERM DEBT
Long-term debt consists of the following:
|
|
June 30, |
|
December 31, |
| ||
(In thousands) |
|
2012 |
|
2011 |
| ||
|
|
(Unaudited) |
|
(Unaudited) |
| ||
|
|
|
|
|
| ||
Revolving Credit Facility |
|
$ |
|
|
$ |
|
|
Term Loan |
|
294,800 |
|
297,000 |
| ||
7 1/8% Senior Notes due 2018 |
|
200,000 |
|
200,000 |
| ||
Subordinated seller notes, non-collateralized, net of unamortized discount with principal and interest payable in either monthly, quarterly or annual installments at effective interest rates ranging from 3.00% to 7.00%, maturing through November 2016 |
|
9,627 |
|
11,033 |
| ||
|
|
504,427 |
|
508,033 |
| ||
Less current portion |
|
(6,115 |
) |
(8,065 |
) | ||
|
|
$ |
498,311 |
|
$ |
499,968 |
|
Amendment to Credit Agreement
On March 11, 2011, the Company entered into an amendment to its Credit Agreement dated as of December 1, 2010 (as amended, the Credit Agreement). The amendment (i) reduced the interest rate margin applicable to the Term Loans under the Credit Agreement by 0.75% to 3.0% and (ii) reduced the LIBOR floor applicable to the Term Loans under the Credit Agreement from 1.5% to 1.0%. The Company incurred $4.1 million of fees related to this amendment, which will be amortized into interest expense over the remaining term of the debt.
Revolving Credit Facility
The $100.0 million Revolving Credit Facility matures on December 1, 2015 and bears interest at LIBOR plus 3.75%, or the applicable rate (as defined in the Credit Agreement). The Revolving Credit Facility requires compliance with various covenants including but not limited to (i) minimum consolidated interest coverage ratio of 3.25:1.00 from October 1, 2011 to September 30, 2012, and 3.50:1.00 thereafter until maturity; (ii) maximum total leverage ratio of 5.00:1.00 until December 31, 2011, 4.50:1.00 from January 1, 2012 to September 30, 2012, and 4.00:1.00 from October 1, 2012 thereafter until maturity; and (iii) maximum annual capital expenditures of 7.5% of consolidated net revenues of the preceding fiscal year with an additional maximum rollover of $15.0 million from the prior years allowance if not expended in the fiscal year for which it is permitted. As of June 30, 2012, the Company had $99.5 million available under the Revolving Credit Facility. Availability under the Revolving Credit Facility as of June 30, 2012 was net of standby letters of credit of approximately $0.5 million. As of June 30, 2012, the Company had no funds drawn on the Revolving Credit Facility. The obligations under the Revolving Credit Facility are senior obligations, are guaranteed by the Companys subsidiaries, and are secured by a first priority perfected interest in the equity interests of the Companys subsidiaries, all of the Companys assets, and all the assets of the Companys subsidiaries.
NOTE G LONG TERM DEBT (CONTINUED)
Term Loan
The $300.0 million Term Loan Facility matures on December 1, 2016 and requires quarterly principal payments of $750,000 that commenced on March 31, 2011. From time to time, mandatory prepayments may be required as a result of excess free cash flow as defined in the Credit Agreement, certain additional debt incurrences, certain asset sales, or other events as defined in the Credit Agreement. The Term Loan Facility bears interest at LIBOR plus 3.0%, or applicable rate (as defined in the Credit Agreement), and includes a 1.0% LIBOR floor. During the first six months of 2012 the Company made a mandatory prepayment on its Term Loan Facility of $700,000. There were no mandatory prepayments made during the first six months of 2011. As of June 30, 2012, the interest rate on the Term Loan Facility was 4.0%. The obligations under the Term Loan Facility are senior obligations, are guaranteed by the Companys subsidiaries, and are secured by a first priority perfected interest in the equity interests of the Companys subsidiaries, all of the Companys assets, and all the assets of the Companys subsidiaries.
71/8% Senior Notes
The 71/8% Senior Notes mature November 15, 2018 and are senior indebtness which is guaranteed on a senior unsecured basis by all of the Companys current and future subsidiaries. Interest is payable semi-annually on May 15 and November 15 of each year, commencing May 15, 2011.
On or prior to November 15, 2013, the Company may redeem up to 35% of the aggregate principal amount of the notes at a redemption price of 107.125% of the principal amount thereof, plus accrued and unpaid interest and additional interest to the redemption date with the proceeds of a public offering of its equity securities. On or after November 15, 2014, the Company may redeem all or from time to time a part of the notes, upon not less than 30 days and not more than 60 days notice, for the twelve month period beginning on November 15, of the indicated years at (i) 103.563% during 2014; (ii) 101.781% during 2015; and (iii) 100.00% during 2016 and thereafter through November 15, 2018.
Subsidiary Guarantees
The Revolving and Term Loan Facilities and the 71/8% Senior Notes are guaranteed by all of the Companys subsidiaries. Separate condensed consolidating information is not included as the Company does not have independent assets or operations. The Guarantees are full and unconditional and joint and several, and any subsidiaries of the Company other than the Guarantor Subsidiaries are minor. There are no restrictions on the ability of our subsidiaries to transfer cash to the Company or to co-guarantors. All consolidated amounts in the Companys financial statements are representative of the combined guarantors.
Debt Covenants
The terms of the Senior Notes, the Revolving Credit Facility, and the Term Loan Facility limit the Companys ability to, among other things, incur additional indebtedness, create liens, pay dividends on or redeem capital stock, make certain investments, make restricted payments, make certain dispositions of assets, engage in transactions with affiliates, engage in certain business activities and engage in mergers, consolidations and certain sales of assets. At June 30, 2012, the Company was in compliance with all covenants under these debt agreements.
NOTE H COMMITMENTS AND CONTINGENT LIABILITIES
Contingencies
The Company is subject to legal proceedings and claims which arise from time to time in the ordinary course of its business, including additional payments under business purchase agreements. In the opinion of management, the amount of ultimate liability, if any, with respect to these actions will not have a materially adverse effect on the financial position, liquidity or results of operations of the Company.
The Company is in a highly regulated industry and receives regulatory agency inquiries from time to time in the ordinary course of its business, including inquiries relating to the Companys billing activities. To date these inquiries have not resulted in material liabilities, but no assurance can be given that future regulatory agencies inquiries will be consistent with the results to date or that any discrepancies identified during a regulatory review will not have a material adverse effect on the Companys consolidated financial statements.
Guarantees and Indemnifications
In the ordinary course of its business, the Company may enter into service agreements with service providers in which it agrees to indemnify or limit the service provider against certain losses and liabilities arising from the service providers performance of the agreement. The Company has reviewed its existing contracts containing indemnification or clauses of guarantees and does not believe that its liability under such agreements is material to the Companys operations.
NOTE I NET INCOME PER COMMON SHARE
Basic per common share amounts are computed using the weighted average number of common shares outstanding during the year. Diluted per common share amounts are computed using the weighted average number of common shares outstanding during the year and dilutive potential common shares. Dilutive potential common shares consist of stock options and restricted shares and are calculated using the treasury stock method.
Net income per share is computed as follows:
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
June 30, |
|
June 30, |
| ||||||||
(In thousands, except share and per share data) |
|
2012 |
|
2011 |
|
2012 |
|
2011 |
| ||||
|
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Net income |
|
$ |
17,386 |
|
$ |
15,431 |
|
$ |
24,941 |
|
$ |
21,644 |
|
|
|
|
|
|
|
|
|
|
| ||||
Shares of common stock outstanding used to compute basic per common share amounts |
|
34,268,941 |
|
33,499,268 |
|
34,110,820 |
|
33,429,502 |
| ||||
Effect of dilutive restricted stock and options (1) |
|
451,548 |
|
866,127 |
|
526,949 |
|
855,011 |
| ||||
Shares used to compute dilutive per common share amounts |
|
34,720,489 |
|
34,365,395 |
|
34,637,769 |
|
34,284,513 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Basic income per share |
|
$ |
0.51 |
|
$ |
0.46 |
|
$ |
0.73 |
|
$ |
0.65 |
|
Diluted income per share |
|
$ |
0.50 |
|
$ |
0.45 |
|
$ |
0.72 |
|
$ |
0.63 |
|
(1) There were no anti-dilutive options for the three or six months ended June 30, 2012 and 2011.
NOTE J SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN
The Companys unfunded noncontributory defined benefit plan (the Plan) covers certain senior executives, is administered by the Company and calls for annual payments upon retirement based on years of service and final average salary. Benefit costs and liabilities balances are calculated based on certain assumptions including benefits earned, discount rates, interest costs, mortality rates and other factors. Actual results that differ from the assumptions are accumulated and amortized over future periods, affecting the recorded obligation and expense in future periods.
The following assumptions were used in the calculation of the net benefit cost and obligation at June 30, 2012:
Discount rate |
|
3.90 |
% |
Average rate of increase in compensation |
|
3.00 |
% |
The Company believes the assumptions used are appropriate; however, changes in assumptions or differences in actual experience may affect our benefit obligation and future expenses. The change in the Plans net benefit obligation for the six months ended June 30, 2012 and 2011 is as follows:
|
|
(in thousands) |
| |
Net benefit cost accrued at December 31, 2011 (unaudited) |
|
$ |
20,230 |
|
Service cost |
|
230 |
| |
Interest cost |
|
190 |
| |
Payments |
|
(525 |
) | |
Net benefit cost accrued at March 31, 2012 (unaudited) |
|
$ |
20,125 |
|
Service cost |
|
230 |
| |
Interest cost |
|
190 |
| |
Payments |
|
(180 |
) | |
Net benefit cost accrued at June 30, 2012 (unaudited) |
|
$ |
20,365 |
|
|
|
(in thousands) |
| |
Net benefit cost accrued at December 31, 2010 (unaudited) |
|
$ |
17,510 |
|
Service cost |
|
247 |
| |
Interest cost |
|
202 |
| |
Payments |
|
(526 |
) | |
Net benefit cost accrued at March 31, 2011 (unaudited) |
|
$ |
17,433 |
|
Service cost |
|
247 |
| |
Interest cost |
|
202 |
| |
Net benefit cost accrued at June 30, 2011 (unaudited) |
|
$ |
17,882 |
|
NOTE K - STOCK-BASED COMPENSATION
The Company utilizes the authoritative guidance using the modified prospective method. Compensation expense for all awards granted is calculated according to the provisions of such guidance.
On May 13, 2010, the shareholders of the Company approved the 2010 Omnibus Incentive Plan (the 2010 Plan) and terminated the Amended and Restated 2002 Stock Incentive and Bonus Plan (the 2002 Plan) and the 2003 Non-Employee Directors Stock Incentive Plan (the 2003 Plan). No new awards will be granted under the 2002 Plan or the 2003 Plan; however, awards granted under either the 2002 Plan or the 2003 Plan that were outstanding on May 13, 2010 remain outstanding and continue to be subject to all of the terms and conditions of the 2002 Plan or the 2003 Plan, as applicable.
NOTE K - STOCK-BASED COMPENSATION (CONTINUED)
The 2010 Plan provides that 2.5 million shares of Common Stock are reserved for issuance, subject to adjustment as set forth in the 2010 Plan; provided, however, that only 1.5 million shares may be issued pursuant to the exercise of incentive stock options. Of these 2.5 million shares, 2.0 million are shares that are newly authorized for issuance under the 2010 Plan and 0.5 million are unissued shares not subject to awards that have been carried over from the shares previously authorized for issuance under the terms of the 2002 Plan and the 2003 Plan. Unless earlier terminated by the Board of Directors, the 2010 Plan will remain in effect until the earlier of (i) the date that is ten years from the date the plan is approved by the Companys shareholders, which is the effective date for the 2010 plan, namely May 13, 2020, or (ii) the date all shares reserved for issuance have been issued.
As of June 30, 2012, of the 2.5 million shares of common stock authorized for issuance under the Companys 2010 Plan, approximately 1,122,000 shares have been issued. During the first six months of 2012, the Company issued approximately 509,000 shares of restricted stock under the 2010 Plan. The total fair value of these grants is $10.4 million. Total unrecognized share-based compensation cost related to unvested restricted stock awards was approximately $14.5 million as of June 30, 2012 and is expected to be expensed as compensation expense over approximately four years.
During the six months ended June 30, 2012 and 2011, no options were cancelled under either the 2002 Plan or the 2003 Plan.
For the six months ended June 30, 2012 and 2011, the Company has included approximately $4.0 million and $3.9 million, respectively, for share-based compensation cost in the accompanying condensed consolidated statements of income for the 2002, 2003 and 2010 Plans. Compensation expense relates to restricted share grants.
NOTE L SEGMENT AND RELATED INFORMATION
The Company has identified three reportable segments in which it operates based on the products and services it provides. The Company evaluates segment performance and allocates resources based on the segments income from operations. The reportable segments are: (i) Patient-Care Services (ii) Distribution, and (iii) Therapeutic solutions. The reportable segments are described further below:
Patient-Care ServicesThis segment consists of the Companys owned and operated patient-care centers. The patient-care centers provide services to design and fit O&P devices to patients. These centers also instruct patients in the use, care and maintenance of the devices. The principal reimbursement sources for the Companys services are:
· Commercial and other, which consist of individuals, rehabilitation providers, private insurance companies, HMOs, PPOs, hospitals, vocational rehabilitation, workers compensation programs and similar sources;
· Medicare, a federally funded health insurance program providing health insurance coverage for persons aged 65 or older and certain disabled persons, which provides reimbursement for O&P products and services based on prices set forth in fee schedules for 10 regional service areas;
NOTE L SEGMENT AND RELATED INFORMATION (CONTINUED)
· Medicaid, a health insurance program jointly funded by federal and state governments providing health insurance coverage for certain persons in financial need, regardless of age, which may supplement Medicare benefits for financially needy persons aged 65 or older; and
· U.S. Department of Veterans Affairs.
The Company estimates that government reimbursement, comprised of Medicare, Medicaid and the U.S. Department of Veterans Affairs, in the aggregate, accounted for approximately 41.3% and 40.6%, of the Companys net sales for the six months ended June 30, 2012 and 2011, respectively.
DistributionThis segment distributes O&P products and components to both the O&P industry and the Companys own patient-care practices. This segment also includes the Companys Fabrication centers which are involved in the fabrication of O&P components for both the O&P industry and the Companys own patient-care centers.
Therapeutic SolutionsThis segment consists of the leasing of rehabilitation equipment from, and the provision of clinical program by, ACP as well the operations of IN, Inc. ACP is a developer of specialized rehabilitation technologies and provides evidence-based clinical programs for post-acute rehabilitation. IN, Inc. specializes in bringing emerging neuromuscular technologies to the O&P market.
OtherThis segment consists of Hanger corporate and Linkia. Linkia is a national managed-care agent for O&P services and a patient referral clearing house.
The accounting policies of the segments are the same as those described in the summary of Significant Accounting Policies in Note B to the consolidated financial statements.
Summarized financial information concerning the Companys reportable segments is shown in the following table. Intersegment sales mainly include sales of O&P components from the Distribution segment to the Patient-Care Services segment and were made at prices which approximate market values.
NOTE L SEGMENT AND RELATED INFORMATION (CONTINUED)
(In thousands) |
|
Patient-Care |
|
Distribution |
|
Therapeutic |
|
Other |
|
Consolidating |
|
Total |
| ||||||
|
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Three Months Ended June 30, 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Customers |
|
$ |
207,791 |
|
$ |
27,413 |
|
$ |
16,356 |
|
$ |
194 |
|
$ |
|
|
$ |
251,754 |
|
Intersegments |
|
|
|
53,147 |
|
1,000 |
|
|
|
(54,147 |
) |
|
| ||||||
Depreciation and amortization |
|
3,381 |
|
324 |
|
2,712 |
|
2,021 |
|
|
|
8,438 |
| ||||||
Income (loss) from operations |
|
40,454 |
|
9,473 |
|
941 |
|
(14,974 |
) |
(168 |
) |
35,726 |
| ||||||
Interest (income) expense |
|
7,552 |
|
830 |
|
1,435 |
|
(2,133 |
) |
|
|
7,684 |
| ||||||
Income (loss) before taxes |
|
32,902 |
|
8,643 |
|
(494 |
) |
(12,841 |
) |
(168 |
) |
28,042 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Three Months Ended June 30, 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Customers |
|
$ |
192,976 |
|
$ |
25,578 |
|
$ |
16,067 |
|
$ |
130 |
|
$ |
|
|
$ |
234,751 |
|
Intersegments |
|
|
|
48,940 |
|
986 |
|
|
|
(49,926 |
) |
|
| ||||||
Depreciation and amortization |
|
3,029 |
|
299 |
|
2,575 |
|
1,793 |
|
|
|
7,696 |
| ||||||
Income (loss) from operations |
|
39,005 |
|
7,479 |
|
811 |
|
(14,371 |
) |
(42 |
) |
32,882 |
| ||||||
Interest (income) expense |
|
7,094 |
|
848 |
|
1,440 |
|
(1,591 |
) |
|
|
7,791 |
| ||||||
Income (loss) before taxes |
|
31,911 |
|
6,631 |
|
(628 |
) |
(12,781 |
) |
(42 |
) |
25,091 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Six Months Ended June 30, 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Customers |
|
$ |
384,163 |
|
$ |
53,653 |
|
$ |
31,688 |
|
$ |
342 |
|
$ |
|
|
$ |
469,846 |
|
Intersegments |
|
|
|
100,716 |
|
1,844 |
|
|
|
(102,560 |
) |
|
| ||||||
Depreciation and amortization |
|
6,797 |
|
648 |
|
5,386 |
|
3,892 |
|
|
|
16,723 |
| ||||||
Income (loss) from operations |
|
65,324 |
|
18,015 |
|
1,208 |
|
(28,420 |
) |
(445 |
) |
55,682 |
| ||||||
Interest (income) expense |
|
15,135 |
|
1,662 |
|
2,875 |
|
(4,211 |
) |
|
|
15,461 |
| ||||||
Income (loss) before taxes |
|
50,189 |
|
16,353 |
|
(1,667 |
) |
(24,209 |
) |
(445 |
) |
40,221 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Capital expenditures |
|
4,677 |
|
220 |
|
1,359 |
|
9,714 |
|
|
|
15,970 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Six Months Ended June 30, 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Customers |
|
$ |
353,527 |
|
$ |
49,038 |
|
$ |
32,323 |
|
$ |
302 |
|
$ |
|
|
$ |
435,190 |
|
Intersegments |
|
|
|
90,567 |
|
1,732 |
|
|
|
(92,299 |
) |
|
| ||||||
Depreciation and amortization |
|
5,990 |
|
583 |
|
5,077 |
|
3,338 |
|
|
|
14,988 |
| ||||||
Income (loss) from operations |
|
61,378 |
|
14,366 |
|
1,562 |
|
(26,099 |
) |
60 |
|
51,267 |
| ||||||
Interest (income) expense |
|
14,210 |
|
1,697 |
|
2,880 |
|
(2,617 |
) |
|
|
16,170 |
| ||||||
Income (loss) before taxes |
|
47,168 |
|
12,669 |
|
(1,318 |
) |
(23,482 |
) |
60 |
|
35,097 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Capital Expenditures |
|
7,058 |
|
630 |
|
2,006 |
|
5,575 |
|
|
|
15,269 |
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Total Assets |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
March 31, 2012 |
|
1,335,910 |
|
188,321 |
|
135,350 |
|
(504,400 |
) |
|
|
1,155,181 |
| ||||||
December 31, 2011 |
|
1,279,481 |
|
170,077 |
|
135,781 |
|
(456,839 |
) |
|
|
1,128,500 |
|
NOTE M CORPORATE OFFICE RELOCATION
The Company moved its corporate headquarters from Bethesda, Maryland to Austin, Texas in 2010. As of January 1, 2012 the relocation of the corporate office was complete. The following is a summary of the costs of the relocation incurred and to be paid in future periods:
NOTE M CORPORATE OFFICE RELOCATION (CONTINUED)
(in thousands) |
|
Employee |
|
Other |
|
Lease |
|
Total |
| ||||
Balance as of December 31, 2011 |
|
$ |
226 |
|
$ |
|
|
$ |
3,085 |
|
$ |
3,311 |
|
Expenses incurred |
|
|
|
|
|
|
|
|
| ||||
Amounts paid |
|
(83 |
) |
|
|
(439 |
) |
(522 |
) | ||||
Balance as of June 30, 2012 |
|
$ |
143 |
|
$ |
|
|
$ |
2,646 |
|
$ |
2,789 |
|
|
|
Employee |
|
Other |
|
Lease |
|
Total |
| ||||
Balance as of December 31, 2010 |
|
$ |
1,895 |
|
$ |
|
|
$ |
5,206 |
|
$ |
7,101 |
|
Expenses incurred |
|
(159 |
) |
576 |
|
|
|
417 |
| ||||
Amounts paid |
|
(1,312 |
) |
(576 |
) |
(1,306 |
) |
(3,194 |
) | ||||
Balance as of June 30, 2011 |
|
$ |
424 |
|
$ |
|
|
$ |
3,900 |
|
$ |
4,324 |
|
ITEM 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
Overview
The following is a discussion of our results of operations and financial condition for the periods described below. This discussion should be read in conjunction with the Consolidated Financial Statements included in this report. Our discussion of our results of operations and financial condition includes various forward-looking statements about our markets, the demand for our products and services and our future results. These statements are based on our current expectations, which are inherently subject to risks and uncertainties. Refer to risk factors disclosed in Part II, Item 1A of this filing as well as the risk factors disclosed in the Companys Annual Report on Form 10-K for the year ended December 31, 2011 for further discussion of risks and uncertainties. Our actual results and the timing of certain events may differ materially from those indicated in the forward looking statements.
Business Overview
General
The goal of Hanger, Inc. (the Company) is to be the worlds premier provider of services and products that enhance human physical capabilities. Built on a legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger is steeped in 150 years of clinical excellence and innovation. We provide orthotic and prosthetic patient-care services, distribute O&P devices and components, manage O&P networks, and provide therapeutic solutions to the broader post acute market. We are the largest owner and operator of orthotic and prosthetic patient-care centers in the United States and, through our distribution subsidiary, Southern Prosthetic Supply, Inc. (SPS), the largest dedicated distributor of O&P products in the United States. We operate in excess of 700 O&P patient-care centers located in 45 states and the District of Columbia and six strategically located distribution facilities. In addition to providing O&P services and products we, through our subsidiary, Linkia LLC (Linkia), manage an O&P provider network and develop programs to manage all aspects of O&P patient care for insurance companies. We also provide therapeutic solutions through our subsidiaries Innovative Neurotronics (IN, Inc.) and Accelerated Care Plus Corp (ACP). IN, Inc. introduces emerging neuromuscular technologies developed through independent research in a collaborative effort with industry suppliers worldwide. ACP is a developer of specialized rehabilitation technologies and a leading provider of evidence-based clinical programs for post-acute rehabilitation serving more than 4,400 long-term care facilities and other sub-acute rehabilitation providers throughout the U.S.
For the three and six months ended June 30, 2012, our net sales were $251.8 million and $469.8 million, respectively, and we recorded net income of $17.4 million and $24.9 million, respectively. For the three and six months ended June 30, 2011, our net sales were $234.8 million and $435.2 million respectively, and we recorded net income of $15.4 million and $21.6 million, respectively.
We have three segmentsPatient-Care Services, Distribution and Therapeutic Solutions. For the three months ended June 30, 2012, net sales attributable to our Patient-Care Services, Distribution and Therapeutic Solutions segments were $207.8 million, $27.4 million and $16.4 million, respectively. For the six months ended June 30, 2012, net sales attributable to our Patient-Care Services, Distribution and Therapeutic Solutions segments were $384.2 million, $53.7 million and $31.7 million, respectively. See Note L to our consolidated financial statements contained herein for further information related to our segments.
Industry Overview
We provide goods and services to the O&P, post-acute, and other rehabilitation markets. We estimate that the O&P patient-care market in the United States is approximately $2.6 billion, of which we account for approximately 29%, and the post-acute rehabilitation and other rehabilitation markets, combined, are approximately $1.3 billion, of which we account for 5%.
We commissioned a study in the past that identified additional opportunities to leverage our expertise beyond the traditional O&P market, and we believe these additional opportunities could potentially expand our available O&P market by an additional $1.4 billion to $4.0 billion.
The O&P patient-care services market is highly fragmented and is characterized by local, independent O&P businesses, with the majority of these businesses generally having a single facility with annual revenues of less than $1.0 million. We do not believe that any single competitor accounts for more than 2% of the countrys total estimated O&P patient-care services revenue.
The O&P services industry is characterized by stable, recurring revenues, primarily resulting from new patients as well as the need for periodic replacement and modification of O&P devices. Based on our experience, the average replacement time for orthotic devices is one to three years, while the average replacement time for prosthetic devices is three to five years. There is also an attendant need for continuing O&P patient-care services. In addition to the inherent need for periodic replacement and modification of O&P devices and continuing care, we expect the demand for O&P services to continue to grow as a result of several key trends, including the aging of the U.S. population, resulting in an increase in incidence of disease, and the demand for new and advanced devices.
We estimate the post-acute rehabilitation market to include approximately 15,000 skilled nursing facilities (SNFs) and to have a market potential of approximately $200 million. We provide technologically advanced rehabilitation equipment and clinical programs to approximately 31% of the post-acute market. We estimate the broader rehabilitation markets, which include independent rehabilitation providers and providers in other post-acute settings, to be approximately $1.1 billion. We currently provide goods and services to very few customers in this portion of the market, however, we believe this market would benefit from our products and services.
Business Description
Patient-Care Services
As of June 30, 2012, we provided O&P patient-care services through over 700 patient-care centers and over 1,195 clinicians in 45 states and the District of Columbia. Substantially all of our clinicians are certified, or are candidates for formal certification, by the O&P industry certifying boards. A clinician manages each of our patient-care centers. Our patient-care centers also employ highly trained technical personnel who assist in the provision of services to patients and who fabricate various O&P devices, as well as office administrators who schedule patient visits, obtain approvals from payors and bill and collect for services rendered.
In our orthotics business, we design, fabricate, fit and maintain a wide range of custom-made braces and other devices (such as spinal, knee and sports-medicine braces) that provide external support to patients suffering from musculoskeletal disorders, such as ailments of the back, extremities or joints and injuries from sports or other activities. In our prosthetics business, we design, fabricate, fit and maintain custom-made artificial limbs for patients who are without limbs as a result of traumatic injuries, vascular diseases, diabetes, cancer or congenital disorders. O&P devices are increasingly technologically advanced and are custom-designed to add functionality and comfort to patients lives, shorten the rehabilitation process and lower the cost of rehabilitation. Patients are referred to Hanger by an attending physician who determines a patients treatment and writes a prescription. Our clinicians then consult with both the referring physician and the patient with a view toward assisting in the design of an orthotic or prosthetic device to meet the patients needs.
The fitting process often involves several stages in order to successfully achieve desired functional and cosmetic results. The clinician creates a cast and takes detailed measurements, frequently using our digital imaging system (Insignia), of the patients residual limb to ensure an anatomically correct fit. Prosthetic devices are custom fabricated and fit by skilled clinicians.
The majority of the orthotic devices provided by us are custom designed, fabricated and fit; the remainder are prefabricated but custom fit.
Custom devices are fabricated by our skilled technicians using plaster castings, measurements and designs made by our clinicians and by utilization of our proprietary Insignia system. The Insignia system replaces plaster casting of a patients residual limb with a computer generated image. Insignia provides a very accurate image, faster turnaround for the patient, and a more professional overall experience. Technicians use advanced materials and technologies to fabricate a custom device under quality assurance guidelines. Custom designed devices that cannot be fabricated at the patient-care centers are fabricated at one of several central fabrication facilities.
To provide timely service to our patients, we employ technical personnel and maintain laboratories at many of our patient-care centers. We have earned a strong reputation within the O&P industry for the development and use of innovative technology in our products, which has increased patient comfort and capability, and can significantly enhance the rehabilitation process. The quality of our services and the success of our technological advances have generated broad media coverage, building our brand equity among payors, patients and referring physicians.
The principal reimbursement sources for our services are:
· Commercial and other, which consist of individuals, rehabilitation providers, private insurance companies, HMOs, PPOs, hospitals, vocational rehabilitation, workers compensation programs and similar sources;
· Medicare, a federally funded health insurance program providing health insurance coverage for persons aged 65 or older and certain disabled persons, which provides reimbursement for O&P products and services based on prices set forth in fee schedules for 10 regional service areas;
· Medicaid, a health insurance program jointly funded by federal and state governments providing health insurance coverage for certain persons in financial need, regardless of age, which may supplement Medicare benefits for financially needy persons aged 65 or older; and
· U.S. Department of Veterans Affairs.
Government reimbursement, comprised of Medicare, Medicaid and the U.S. Department of Veterans Affairs, in the aggregate, accounted for approximately 41.3% and 40.6% of our net sales for the six months ended June 30, 2012 and 2011, respectively. These payors have set maximum reimbursement levels for O&P services and products. Medicare prices are adjusted each year based on the Consumer Price Index-Urban (CPIU) unless Congress acts to change or eliminate the adjustment. The Medicare price (decreases)/increases for 2012, 2011, 2010, 2009, and 2008 were 2.4%, (0.1%), 0.0%, 5.0%, and 2.7%, respectively. There can be no assurance that future changes will not reduce reimbursements for O&P services and products from these sources.
We enter into contracts with third-party payors that allow us to perform O&P services for a referred patient and be paid under the contract with the third- party payor. These contracts typically have a stated term of one to three years. These contracts generally may be terminated without cause by either party on 60 to 90 days notice or on 30 days notice if we have not complied with certain licensing, certification, program standards, Medicare or Medicaid requirements or other regulatory requirements. Reimbursement for services is typically based on a fee schedule negotiated with the third-party payor that reflects various factors, including geographic area and number of persons covered.
Through the normal course of business, we receive patient deposits on devices not yet delivered. At June 30, 2012 and December 31 2011, we held $1.2 million and $0.5 million of deposits, respectively, from our patients.
Provider Network Management
Linkia is the only provider network management company dedicated solely to serving the O&P market. Linkia is dedicated to managing the O&P services of national and regional insurance companies. Linkia partners with healthcare insurance companies by securing a national or regional contract either as a preferred provider or to manage their O&P network of providers. Linkias network now includes approximately 1,050 O&P provider locations, including approximately 360 independent providers. As of June 30, 2012, Linkia had 53 contracts with national and regional providers.
Distribution Services
We distribute O&P components to independent customers and to our own patient-care centers through our wholly-owned subsidiary, SPS, which is the nations largest dedicated O&P distributor. We are also a leading manufacturer and distributor of therapeutic footwear for diabetic patients in the podiatric market. SPS maintains in inventory approximately 27,000 individual SKUs manufactured by more than 300 different companies. SPS operates distribution facilities in California, Florida, Georgia, Illinois, Pennsylvania, and Texas, which allows us to deliver products via ground shipment anywhere in the contiguous United States typically within two business days.
Our Distribution business enables us to:
· centralize our purchasing and thus lower our material costs by negotiating purchasing discounts from manufacturers;
· reduce our patient-care center inventory levels and improve inventory turns;
· perform inventory quality control;
· encourage our patient-care centers to use clinically appropriate products that enhance our profit margins; and
· coordinate new product development efforts with key vendor partners.
Marketing of our Distribution services is conducted on a national basis through a dedicated sales force, print and e-commerce catalogues, and exhibits at industry and medical meetings and conventions. We direct specialized catalogues to segments of the healthcare industry, such as orthopedic surgeons, physical and occupational therapists, and podiatrists.
Therapeutic Solutions
We provide therapeutic solutions to the O&P market and post-acute rehabilitation market through our subsidiaries IN, Inc. and ACP. ACP is the nations leading provider of rehabilitation technologies and integrated clinical programs to rehabilitation providers. ACPs unique value proposition is to provide its customers with a full-service total solutions approach encompassing proven medical technology, evidence based clinical programs, and continuous onsite therapist education and training. ACPs services support increasingly advanced treatment options for a broader patient population and more medically complex conditions. ACP has contracts to serve more than 4,400 skilled nursing facilities nationwide, including 21 of the 25 largest national providers. ACPs contracts contain negotiated pricing and service levels with terms ranging from one to five years. ACP generally bills its customers monthly and revenue is recognized based upon the contractual terms of the agreements.
IN, Inc. specializes in the product development and commercialization of emerging products in the O&P and Rehabilitation markets. Working with inventors under licensing and consulting agreements, IN, Inc. commercializes the design, obtains regulatory approvals, develops clinical protocols for the technology, and then introduces the devices to the marketplace through a variety of distribution channels. IN, Inc. currently has two commercial products: the WalkAide System which benefits patients with a condition referred to as drop foot and the V-Hold which is active vacuum technology used in lower extremity prosthetic devices. The V-Hold is primarily sold through our patient care centers. The WalkAide System is currently reimbursable for Medicare beneficiaries with foot drop due to incomplete spinal cord injuries. IN, Inc. is currently conducting clinical trials in an effort to gain additional coverage for stroke patients with foot drop, which represents the largest potential foot drop patient population. These trials are now fully enrolled with submission of data to CMS anticipated in 2013. In addition to reimbursement with Medicare, IN, Inc. has been working with commercial insurance companies and has had limited success in receiving coverage for the WalkAide. The WalkAide is sold in the United States through our patient-care centers and SPS. IN, Inc. is also marketing the WalkAide internationally through a network of distributors in Europe, the Middle East/Africa, Latin America, Canada, and Asia.
Critical Accounting Policies and Estimates
Our analysis and discussion of our financial condition and results of operations is based upon our Consolidated Financial Statements that have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. GAAP provides the framework from which to make these estimates, assumptions and disclosures. We have chosen accounting policies within GAAP that management believes are appropriate to accurately and fairly report our operating results and financial position in a consistent manner. Management regularly assesses these policies in light of current and forecasted economic conditions. Our accounting policies are stated in Note B to the Consolidated Financial Statements included elsewhere in this report. We believe the following accounting policies are critical to understanding our results of operations and the more significant judgments and estimates used in the preparation of our Consolidated Financial Statements.
· Revenue Recognition: Revenues in our Patient-Care Services segment are derived from the sale of O&P devices and the maintenance and repair of existing devices and are recorded net of all contractual adjustments and discounts. The sale of O&P devices includes the design, fabrication, assembly, fitting and delivery of a wide range of braces, limbs and other devices. Revenues from the sale of these devices are recorded when (i) acceptance by and delivery to the patient has occurred; (ii) persuasive evidence of an arrangement exists and there are no further obligations to the patient; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. Revenues from maintenance and repairs are recognized when the service is provided. Revenues on the sale of O&P devices to customers by the Distribution segment are recorded upon the shipment of products, in accordance with the terms of the invoice, net of merchandise returns received and the amount established for anticipated returns. Discounted sales are recorded at net realizable value. Revenues in our Therapeutic Solutions segment are primarily derived from leasing rehabilitation technology combined with clinical therapy programs and education and training. The revenue is recorded on a monthly basis according to terms of the contracts with our customers.
Certain accounts receivable may be uncollectible, even if properly pre-authorized and billed. Regardless of the balance, accounts receivable amounts are periodically evaluated to assess collectability. In addition to the actual bad debt expense recognized during collection activities, we estimate the amount of potential bad debt expense that may occur in the future. This estimate is based upon our historical experience as well as a review of our receivable balances.
On a quarterly basis, we evaluate cash collections, accounts receivable balances and write-off activity to assess the adequacy of our allowance for doubtful accounts. Additionally, a company-wide evaluation of collectability of receivable balances older than 180 days is performed at least semi-annually, the results of which are used in the next allowance analysis. In these detailed reviews, the accounts net realizable value is estimated after considering the customers payment history, past efforts to collect on the balance and the outstanding balance, and a specific reserve is recorded if needed. From time to time, we may outsource the collection of such accounts to collection agencies after internal collection efforts are exhausted. In cases where valid accounts receivable cannot be collected, the uncollectible account is written off to bad debt expense.
The following represents the composition of our accounts receivable balance by type of payor:
June 30, 2012 |
|
|
|
|
|
|
|
|
| ||||
(In thousands) |
|
0-60 days |
|
61-120 days |
|
Over 120 days |
|
Total |
| ||||
Patient Care Services |
|
|
|
|
|
|
|
|
| ||||
Commercial insurance |
|
$ |
45,106 |
|
$ |
9,444 |
|
$ |
14,665 |
|
$ |
69,215 |
|
Private pay |
|
4,489 |
|
4,158 |
|
8,310 |
|
16,957 |
| ||||
Medicaid |
|
12,266 |
|
2,899 |
|
3,626 |
|
18,791 |
| ||||
Medicare |
|
27,977 |
|
5,050 |
|
6,329 |
|
39,356 |
| ||||
VA |
|
2,102 |
|
299 |
|
248 |
|
2,649 |
| ||||
Distribution & Therapeutic Solutions Trade accounts receivable |
|
12,538 |
|
3,300 |
|
4,127 |
|
19,965 |
| ||||
|
|
$ |
104,478 |
|
$ |
25,150 |
|
$ |
37,305 |
|
$ |
166,933 |
|
December 31, 2011 |
|
|
|
|
|
|
|
|
| ||||
(In thousands) |
|
0-60 days |
|
61-120 days |
|
Over 120 days |
|
Total |
| ||||
Patient Care Services |
|
|
|
|
|
|
|
|
| ||||
Commercial insurance |
|
$ |
50,136 |
|
$ |
9,594 |
|
$ |
11,759 |
|
$ |
71,489 |
|
Private pay |
|
3,936 |
|
3,791 |
|
9,219 |
|
16,946 |
| ||||
Medicaid |
|
12,018 |
|
3,678 |
|
4,173 |
|
19,869 |
| ||||
Medicare |
|
25,438 |
|
3,489 |
|
4,433 |
|
33,360 |
| ||||
VA |
|
1,428 |
|
373 |
|
159 |
|
1,960 |
| ||||
Distribution & Therapeutic Solutions Trade accounts receivable |
|
11,367 |
|
2,663 |
|
3,200 |
|
17,230 |
| ||||
|
|
$ |
104,323 |
|
$ |
23,588 |
|
$ |
32,943 |
|
$ |
160,854 |
|
· Inventories: Inventories, which consist principally of raw materials, work in process and finished goods, are stated at the lower of cost or market using the first-in, first-out method. At our Patient-Care Services segment, we calculate cost of goods soldmaterials in accordance with the gross profit method for all reporting periods. We base the estimates used in applying the gross profit method on the actual results of the most recently completed physical inventory and other factors, such as sales mix and purchasing trends among other factors. Cost of goods soldmaterials is adjusted once the annual physical inventory is taken and the valuation is completed in the fourth quarter. We treat these inventory adjustments as changes in accounting estimates.
· Goodwill and Other Intangible Assets: Goodwill represents the excess of purchase price over the fair value of net identifiable assets of purchased businesses. We assess goodwill for impairment annually on October 1, or when events or circumstances indicate that the carrying value of the reporting units may not be recoverable. Any impairment would be recognized by a charge to operating results and a reduction in the carrying value of the intangible asset. Our annual impairment test for goodwill primarily utilizes the income approach and considers the market approach and the cost approach in determining the value of our reporting units.
Non-compete agreements are recorded based on agreements entered into by us and are amortized, using the straight-line method, over their terms ranging from five to seven years. Other definite-lived intangible assets are recorded at cost and are amortized, using the straight-line method, over their estimated useful lives of up to 17 years. Whenever the facts and circumstances indicate that the carrying amounts of these intangibles may not be recoverable, we review and assess the future cash flows expected to be generated from the related intangible for possible impairment. Any impairment would be recognized as a charge to operating results and a reduction in the carrying value of the intangible asset. As of October 1, 2011, there were no indicators of impairment as the fair value of the reporting units is substantially in excess of their carrying value.
· Income taxes: We are required to estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating the actual current tax liability together with assessing temporary differences in recognition of income (loss) for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in the Consolidated Balance Sheet. We then assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent that we believe that recovery is not likely, we establish a valuation allowance against the deferred tax asset.
We recognize liabilities for uncertain tax positions based on a two-step process. The first step requires us to determine if the weight of available evidence indicates that the tax position has met the threshold for recognition; therefore, we must evaluate whether it is more likely than not that the position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step requires us to measure the tax benefit of the tax position taken, or expected to be taken, in an income tax return as the largest amount that is more than 50% likely of being realized upon ultimate settlement. This measurement step is inherently complex and requires subjective estimations of such amounts to determine the probability of various possible outcomes. We re-evaluate the uncertain tax positions each quarter based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, expirations of statutes of limitation, effectively settled issues under audit, and new audit activity. Such a change in recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision in the period.
Although we believe the measurement of our liabilities for uncertain tax positions is reasonable, no assurance can be given that the final outcome of these matters will not be different than what is reflected in the historical income tax provisions and accruals. If additional taxes are assessed as a result of an audit or litigation, it could have a material effect on the income tax provision and net income in the period or periods for which that determination is made. We operate within multiple taxing jurisdictions and are subject to audit in these jurisdictions. These audits can involve complex issues which may require an extended period of time to resolve and could result in additional assessments of income tax. We believe adequate provisions for income taxes have been made for all periods.
Guidance and Outlook
The Company expects full year 2012 revenues of between $970 million and $990 million resulting from comparable store sales growth in our Patient Care Services segment of 3% to 5% and growth in our Distribution segment of 3% to 5%. We expect flat to slightly higher revenues in our Therapeutic Solution Services segment for the year, with sales in the first half of the year down then trending up in the second half as the rate of new contract sales accelerates. The Company anticipates diluted earnings per share of between $1.74 and $1.78, which includes approximately $0.01 for one-time training costs related to the implementation of our new pratice management system.
As in past years, the Companys goal is to increase operating margins by twenty to forty basis points. The Company anticipates generating cash flow from operations between $70 million and $80 million in 2012 and investing a total of $40 million to $50 million in capital additions. During 2012 the Company will continue its acquisition program with a goal of closing acquisitions that total approximately $20 million in annualized revenues.
Results of Operations
The following table sets forth for the periods indicated certain items from our Consolidated Statements of Operations as a percentage of our net sales:
|
|
Three Months Ended |
|
Six Months Ended |
| ||||
|
|
June 30, |
|
June 30, |
| ||||
|
|
2012 |
|
2011 |
|
2011 |
|
2010 |
|
|
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
100.0 |
% |
100.0 |
% |
100.0 |
% |
100.0 |
% |
Cost of goods sold - materials |
|
29.0 |
|
30.5 |
|
29.2 |
|
30.3 |
|
Personnel costs |
|
33.1 |
|
34.3 |
|
34.5 |
|
36.3 |
|
Other operating expenses |
|
20.4 |
|
19.8 |
|
19.0 |
|
19.8 |
|
Relocation expenses |
|
|
|
2.0 |
|
0.0 |
|
1.6 |
|
Depreciation and amortization |
|
3.4 |
|
2.2 |
|
3.3 |
|
2.3 |
|
Income from operations |
|
14.2 |
|
11.2 |
|
14.0 |
|
9.7 |
|
Interest expense |
|
3.1 |
|
3.6 |
|
3.3 |
|
3.9 |
|
Income before taxes |
|
11.1 |
|
7.6 |
|
10.7 |
|
5.8 |
|
Provision for income taxes |
|
4.2 |
|
2.9 |
|
4.1 |
|
2.2 |
|
Net income |
|
6.9 |
% |
4.7 |
% |
6.6 |
% |
3.6 |
% |
Three Months Ended June 30, 2012 Compared to the Three Months Ended June 30, 2011
Net Sales. Net sales for the three months ended June 30, 2012 increased $17.0 million, or 7.2%, to $251.6 million for the second quarter of 2012 compared to $234.8 million for the same period of 2011. The increase was the result of a $8.8 million, or 4.6%, increase in same-center sales in the Patient-Care Services segment; a $5.9 million increase from acquired entities; a $1.8 million, or 7.0%, increase in sales in the Distribution segment; and a $0.3 million increase from the Therapeutic Solutions segment.
Cost of Goods Sold - Materials. Cost of goods sold - materials for the three months ended June 30, 2012 was $72.9 million, an increase of $4.4 million over $68.5 million for the three months ended June 30, 2011. The increase was the result of growth in sales. Cost of goods sold - materials as a percentage of net sales decreased 20 basis points due to revenue mix.
Personnel Costs. Personnel costs for the three months ended June 30, 2012 increased by $2.4 million to $83.4 million from $81.0 million for the three months ended June 30, 2011. The increase was due to costs from acquired entities and increased employee benefit costs, staffing and merit increases. As a percentage of net sales, personnel costs decreased 140 basis points to 33.1% in 2012 from 34.5% in 2011 due to leveraging existing headcount over increased sales volume.
Other Operating Expenses. Other operating expenses for the three months ended June 30, 2012 increased $6.7 million, to $51.3 million, from $44.6 million for the three months ended June 30, 2011. The increase was primarily due to: (i) the addition of $1.1 million in operating expenses from acquired entities; (ii) $2.0 million in increased expenses related bad debt; (iii) $3.1 million in increased incentive compensation; and (iv) $0.5 million related to Instride trials. Other operating expenses as a percentage of net revenues increased 1.4% to 20.4% in 2012 from 19.0% in the prior year due to the increase expenses discussed above.
Relocation Expenses. As of January 1, 2012, we had completed the relocation of our corporate office from Bethesda, Maryland to Austin, Texas. During the three months ended June 30, 2011, we incurred nominal costs related to the relocation of employees.
Depreciation and Amortization. Depreciation and amortization for the three months ended June 30, 2012 increased $0.7 million, to $8.4 million, compared to $7.7 million in the second quarter of 2011. The increase was primarily due to operating assets purchased over the last 12 months.
Income from Operations. Income from operations increased $2.8 million, to $35.7 million, for the three months ended June 30, 2012 compared to $32.9 million for the three months ended June 30, 2011 due to increased sales volume and improved cost of materials as a percentage of net revenues.
Interest Expense. Interest expense remained consistent, at was $7.7 million for the three months ended June 30, 2012, compared to $7.8 million, for the three months ended June 30, 2011. Variable interest rates were comparable in the two periods and the Company made required repayments of debt.
Provision for Income Taxes. The provision for income taxes for the three months ended June 30, 2012 was $10.7 million, or 38.0% of pre-tax income, compared to $9.7 million, or 38.5% of pre-tax income, for the three months ended June 30, 2011. The effective tax rate consists principally of the 35% federal statutory tax rate and state income taxes, less permanent tax differences. The 2011 period has a higher effective tax rate due to higher state income tax rates and discrete tax items.
Net Income. Net income increased $2.0 million, to $17.4 million, for three months ended June 30, 2012, from $15.4 million for the three months ended June 30, 2011, due primarily to increased sales volume.
Six Months Ended June 30, 2012 Compared to the Six Months Ended June 30, 2011
Net Sales. Net sales for the six months ended June 30, 2012 increased $34.6 million, or 8.0%, to $469.8 million from $435.2 million for the same period in 2011. The sales increase was driven by a $20.2 million, or 5.7%, increase in same-center sales in the Patient-Care Services segment; a $10.6 million increase from acquired entities; a $4.6 million or 9.4% increase in sales in the Distribution segment; and a $0.7 million decrease from the Therapeutic Solutions segment.
Cost of Goods Sold - Materials. Cost of goods sold - materials for the six months ended June 30, 2012 was $137.0 million, an increase of $10.4 million over $126.6 million for the six months ended June 30, 2011. The increase was the result of growth in sales. Cost of goods sold - materials as a percentage of net sales increased 10 basis points due to mix of revenue.
Personnel Costs. Personnel costs for the six months ended June 30, 2012 increased by $7.2 million to $167.1 million from $159.9 million for the six months ended June 30, 2011. The increase was due to costs from acquired entities and increased employee benefit costs, staffing and merit increases. As a percentage of net sales, personnel costs decreased 1.1% to 35.6% in 2012 from 36.7% in 2011 due to leveraging headcount over increased sales volume.
Other Operating Expenses. Other operating expenses for the six months ended June 30, 2012 increased $11.4 million, to $93.4 million, from $82.0 million for the six months ended June 30, 2011. The increase was primarily due to: (i) the addition of $2.1 million in operating expenses from acquired entities; (ii) $3.4 million in increased expenses related to bad debt; (iii) $4.0 million in increased incentive compensation; (iv) $1.1 million related to Instride trials; and (v) 0.9 million in other costs. Other operating expenses as a percentage of net revenues increased 110 basis points to 19.9% in 2012 from 18.8% in the prior year due to the increase expenses discussed above.
Relocation Expenses. As of January 1, 2012, we had completed the relocation of our corporate office from Bethesda, Maryland to Austin, Texas. During the six months ended June 30, 2011, we incurred $0.4 million of employee relocation costs.
Depreciation and Amortization. Depreciation and amortization for the six months ended June 30, 2012 increased $1.7 million, to $16.7 million, compared to $15.0 million in the first half of 2011. The increase was primarily due to operating assets purchased over the last 12 months.
Income from Operations. Income from operations increased $4.4 million, to $55.7 million, for the six months ended June 30, 2012 compared to $51.3 million for the six months ended June 30, 2011 due to increased sales volume.
Interest Expense. Interest expense decreased $0.7 million for the six months ended June 30, 2012, to $15.5 million, compared to $16.2 million for the six months ended June 30, 2011, primarily due to lower interest rates resulting from the amendment to our credit facilities in March 2011.
Provision for Income Taxes. The provision for income taxes for the six months ended June 30, 2012 was $15.3 million, or 38.0% of pre-tax income, compared to $13.5 million, or 38.3% of pre-tax income, for the six months ended June 30, 2011. The effective tax rate consists principally of the 35% federal statutory tax rate and state income taxes, less permanent tax differences. The 2011 period has a higher effective tax rate due to higher state income tax rates and discrete tax items.
Net Income. Net income increased $3.3 million, to $24.9 million, for six months ended June 30, 2012, from $21.6 million for the six months ended June 30, 2011, due primarily to increased sales volume.
Financial Condition, Liquidity and Capital Resources
Cash Flows
Our working capital at June 30, 2012 was $265.9 million, compared to $201.6 million at June 30, 2011. The increase in working capital is primarily due to increases in cash, inventory, and accounts receivable. Days sales outstanding (DSO), which is the number of days between the billing date of O&P services and the date of receipt of payment thereof, for the six months ended June 30, 2012 increased to 54 days from 50 days for the same period last year. Net cash provided by operating activities was $27.0 million for six months ended June 30, 2012 compared to $10.6 million for the same period in the prior year. The increase in cash provided by operating activities in the current year resulted primarily from increased net income, and a decrease in incentive compensation payments in 2012.
Net cash used in investing activities was $25.5 million for the six months ended June 30, 2012, compared to $21.2 million in the prior year. In the first six months of 2012, we acquired five O&P companies operating eight patient-care centers at an aggregate purchase price of $8.6 million. During the same period in 2011, we acquired three O&P companies operating four patient-care center for an aggregate purchase price of $7.3 million. Additionally, in the first six months of 2012, we invested $16.0 million in capital assets, compared to $15.2 million for the same period in 2011. Capital assets acquired in the first six months of 2012 related to the development of the Companys new practice management system, leasehold improvements in our patient care practices and computer equipment purchases. Additionally, during the first six months of 2012 we restricted $3.1 million of cash in order to eliminate letters of credit obligations under our revolving credit agreement.
Net cash used by financing activities was $2.8 million and $6.2 million for the six months ended June 30, 2012 and 2011, respectively. During the first six months of 2012 we: (i) repaid $2.2 million related to term loan borrowings under our credit facilities (Term Loans); (ii) made $2.5 million of required repayments of promissory notes issued in connection with acquisitions (Seller Notes); and (iii) received $1.6 million of proceeds from issuance of stock under employee stock compensation plans. During the first six months of 2011 we: (i) borrowed and repaid $10.0 million under our revolving credit facility; (ii) repaid $1.5 million related to Term Loans; (iii) made $2.1 million of required repayments of Seller Notes; (iv) incurred $4.2 million of financing costs related to the amendment to our credit agreement in the first quarter of 2011; and (v) received $0.6 million of proceeds from issuance of stock under employee stock compensation plans.
Debt
Long-term debt consisted of the following:
|
|
June 30, |
|
December 31, |
| ||
|
|
2012 |
|
2011 |
| ||
|
|
(Unaudited) |
|
(Unaudited) |
| ||
(In thousands) |
|
|
|
|
| ||
Revolving Credit Facility |
|
$ |
|
|
$ |
|
|
Term Loan |
|
294,800 |
|
297,000 |
| ||
7 1/8% Senior Notes due 2018 |
|
200,000 |
|
200,000 |
| ||
Subordinated seller notes, non-collateralized, net of unamortized discount with principal and interest payable in either monthly, quarterly or annual installments at effective interest rates ranging from 3.00% to 7.00%, maturing through November 2016 |
|
9,627 |
|
11,033 |
| ||
|
|
504,427 |
|
508,033 |
| ||
Less current portion |
|
(6,115 |
) |
(8,065 |
) | ||
|
|
$ |
498,311 |
|
$ |
499,968 |
|
Amendment to Credit Agreement
On March 11, 2011, the Company entered into an amendment to its Credit Agreement dated as of December 1, 2010 (as amended, the Credit Agreement). The amendment (i) reduced the interest rate margin applicable to the Term Loans under the Credit Agreement by 0.75% to 3.0% and (ii) reduced the LIBOR floor applicable to the Term Loans under the Credit Agreement from 1.5% to 1.0%. The Company incurred $4.1 million of fees related to this amendment, which will be amortized into interest expense over the remaining term of the debt.
Revolving Credit Facility
The $100.0 million Revolving Credit Facility matures on December 1, 2015 and bears interest at LIBOR plus 3.75%, or the applicable rate (as defined in the Credit Agreement). The Revolving Credit Facility requires compliance with various covenants including but not limited to (i) minimum consolidated interest coverage ratio of 3.25:1.00 from October 1, 2011 to September 30, 2012, and 3.50:1.00 thereafter until maturity; (ii) maximum total leverage ratio of 5.00:1.00 until December 31, 2011, 4.50:1.00 from January 1, 2012 to September 30, 2012, and 4.00:1.00 from October 1, 2012 thereafter until maturity; and (iii) maximum annual capital expenditures of 7.5% of consolidated net revenues of the preceding fiscal year with an additional maximum rollover of $15.0 million from the prior years allowance if not expended in the fiscal year for which it is permitted. As of June 30, 2012, the Company had $99.5 million available under the Revolving Credit Facility. Availability under the Revolving Credit Facility as of June 30, 2012 was net of standby letters of credit of approximately $0.5 million. As of June 30, 2012, the Company had no funds drawn on the Revolving Credit Facility. The obligations under the Revolving Credit Facility are senior obligations, are guaranteed by the Companys subsidiaries, and are secured by a first priority perfected interest in the equity interests of the Companys subsidiaries, all of the Companys assets, and all the assets of the Companys subsidiaries.
Term Loan
The $300.0 million Term Loan Facility matures on December 1, 2016 and requires quarterly principal payments of $750,000 that commenced on March 31, 2011. From time to time, mandatory prepayments may be required as a result of excess free cash flow as defined in the Credit Agreement, certain additional debt incurrences, certain asset sales, or other events as defined in the Credit Agreement. The Term Loan Facility bears interest at LIBOR plus 3.0%, or applicable rate (as defined in the Credit Agreement), and includes a 1.0% LIBOR floor. During the first six months of 2012 the Company made a mandatory prepayment on its Term Loan Facility of $700,000. There were no mandatory prepayments made during the first six months of 2011. As of June 30, 2012, the interest rate on the Term Loan Facility was 4.0%. The obligations under the Term Loan Facility are senior obligations, are guaranteed by the Companys subsidiaries, and are secured by a first priority perfected interest in the equity interests of Companys subsidiaries, all of the Companys assets, and all the assets of the Companys subsidiaries.
71/8% Senior Notes
The 71/8% Senior Notes mature November 15, 2018 and are senior indebtness which is guaranteed on a senior unsecured basis by all of the Companys current and future subsidiaries. Interest is payable semi-annually on May 15 and November 15 of each year, commencing May 15, 2011.
On or prior to November 15, 2013, the Company may redeem up to 35% of the aggregate principal amount of the notes at a redemption price of 107.125% of the principal amount thereof, plus accrued and unpaid interest and additional interest to the redemption date with the proceeds of a public offering of its equity securities. On or after November 15, 2014, the Company may redeem all or from time to time a part of the notes, upon not less than 30 days and not more than 60 days notice, for the twelve month period beginning on November 15, of the indicated years at (i) 103.563% during 2014; (ii) 101.781% during 2015; and (iii) 100.00% during 2016 and thereafter through November 15, 2018.
Subsidiary Guarantees
The Revolving and Term Loan Facilities and the 71/8% Senior Notes are guaranteed by all of the Companys subsidiaries. Separate condensed consolidating information is not included as the Company does not have independent assets or operations. The Guarantees are full and unconditional and joint and several, and any subsidiaries of the Company other than the Guarantor Subsidiaries are minor. There are no restrictions on the ability of our subsidiaries to transfer cash to the Company or to co-guarantors. All consolidated amounts in the Companys financial statements are representative of the combined guarantors.
Debt Covenants
The terms of the Senior Notes, the Revolving Credit Facility, and the Term Loan Facility limit the Companys ability to, among other things, incur additional indebtedness, create liens, pay dividends on or redeem capital stock, make certain investments, make restricted payments, make certain dispositions of assets, engage in transactions with affiliates, engage in certain business activities and engage in mergers, consolidations and certain sales of assets. At June 30, 2012, the Company was in compliance with all covenants under these debt agreements.
General
As of June 30, 2012, $294.8 million, or 58.4%, of our total debt of $504.4 million was subject to variable interest rates. We believe that, based on current levels of operations and anticipated growth, cash generated from operations, together with other available sources of liquidity, including borrowings available under the Revolving Credit Facility, will be sufficient for at least the next twelve months to fund anticipated capital expenditures, to fund our acquisition plans and make required payments of principal and interest on our debt, including payments due on our outstanding debt.
Obligations and Commercial Commitments
The following table sets forth our contractual obligations and commercial commitments as of June 30, 2012 (unaudited):
|
|
|
|
Payments Due by Period |
|
|
|
|
|
|
|
|
| |||||||||
|
|
Remainder of 2012 |
|
2013 |
|
2014 |
|
2015 |
|
2016 |
|
Thereafter |
|
Total |
| |||||||
(In thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt |
|
$ |
4,022 |
|
$ |
5,629 |
|
$ |
4,694 |
|
$ |
4,512 |
|
$ |
285,442 |
|
$ |
200,128 |
|
$ |
504,427 |
|
Interest payments on long-term debt |
|
20,356 |
|
26,131 |
|
25,913 |
|
25,741 |
|
24,181 |
|
26,721 |
|
$ |
149,043 |
| ||||||
Operating leases |
|
21,859 |
|
37,473 |
|
30,219 |
|
20,668 |
|
14,813 |
|
32,614 |
|
$ |
157,646 |
| ||||||
Capital leases and other long-term obligations (1) |
|
7,795 |
|
14,211 |
|
12,768 |
|
11,057 |
|
5,094 |
|
12,982 |
|
$ |
63,907 |
| ||||||
Total contractual cash obligations |
|
$ |
54,032 |
|
$ |
83,444 |
|
$ |
73,594 |
|
$ |
61,978 |
|
$ |
329,530 |
|
$ |
272,445 |
|
$ |
875,023 |
|
(1) Other long-term obligations include commitments under our SERP plan. Refer to Note K of the Companys Annual Report on Form 10-K for additional disclosure.
The carrying value of our long-term debt, excluding the Senior Notes, approximates fair value based on rates currently available to the Company for debt with similar terms and remaining maturities (level 2). The fair value of the Senior Notes, as of June 30, 2012, was $206.0 million, as compared to the carrying value of $200.0 million at that date. The fair values of the Senior Notes were based on the quoted market price as of June 30, 2012 (level 1).
Market Risk
We are exposed to the market risk that is associated with changes in interest rates. As of June 30, 2012, all our outstanding debt, with the exception of the $294.86 million borrowed under the Term Loan Facility, was subject to fixed interest rates (see Item 3 below).
Forward Looking Statements
This report contains forward-looking statements setting forth our beliefs or expectations relating to future revenues, contracts and operations, as well as the results of an internal investigation and certain legal proceedings. Actual results may differ materially from projected or expected results due to changes in the demand for our O&P products and services, uncertainties relating to the results of operations or recently acquired O&P patient-care centers, our ability to enter into and derive benefits from managed-care contracts, our ability to successfully attract and retain qualified O&P clinicians, federal laws governing the health-care industry, uncertainties inherent in incomplete investigations and legal proceedings, governmental policies affecting O&P operations and other risks and uncertainties generally affecting the health-care industry. Readers are cautioned not to put undue reliance on forward-looking statements. Refer to risk factors disclosed in Part II, Item 1A of this filing as well as the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2011 for discussion of risks and uncertainties. We disclaim any intent or obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
We have existing obligations relating to our 71/8% Senior Notes, Term Loan Facility, Revolver and Subordinated Seller Notes. As of June 30, 2012, we had cash flow exposure to the changing interest rates on the $294.8 million borrowed under the Term Loan Facility. The other obligations have fixed interest rates.
Presented below is an analysis of our financial instruments as of June 30, 2012 that are sensitive to changes in interest rates. The table demonstrates the changes in estimated annual cash flow related to the outstanding balance under the Term Loan Facility, calculated for an instantaneous parallel shift in interest rates, plus or minus 50 basis points (BPS), 100 BPS and 150 BPS. The LIBOR floor and applicable rate pursuant to the Term Loans under the Credit Agreement prevents the rate from dropping below 4.0%. As of June 30, 2012, the current LIBOR and applicable rate, is 4.0%; therefore, a 75 BPS increase or decrease in LIBOR would not reduce or increase estimated annual cash flows related to the outstanding balance on the Term Loan Facility.
Cash Flow Risk |
|
Annual Interest Expense Given an Interest Rate |
|
No Change in |
|
Annual Interest Expense Given an Interest |
| |||||||||||||||
(In thousands) |
|
(150 BPS) |
|
(100 BPS) |
|
(50 BPS) |
|
|
|
50 BPS |
|
100 BPS |
|
150 BPS |
| |||||||
Term Loan |
|
$ |
11,792 |
|
$ |
11,792 |
|
$ |
11,792 |
|
$ |
11,792 |
|
$ |
11,792 |
|
$ |
12,529 |
|
$ |
14,003 |
|
ITEM 4. Controls and Procedures
Disclosure Controls and Procedures
The Companys disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by it in its periodic reports filed with the Securities and Exchange Commission is recorded, processed, summarized and reported, within the time periods specified in the Commissions rules and forms. Based on an evaluation of the Companys disclosure controls and procedures conducted by the Companys Chief Executive Officer and Chief Financial Officer, such officers concluded that the Companys disclosure controls and procedures were effective as of June 30, 2012 to ensure that information required to be disclosed in the reports filed under the Exchange Act was accumulated and communicated to management, including the Companys Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.
Change in Internal Control Over Financial Reporting
In accordance with Rule 13a-15(d) under the Securities Exchange Act of 1934, management, with the participation of the Companys Chief Executive Officer and Chief Financial Officer, determined that there was no change in the Companys internal control over financial reporting that occurred during the three months ended June 30, 2012, that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting.
Part I, Item 1A (Risk Factors) of the Companys Annual Report on Form 10-K for the year ended December 31, 2011 sets forth information relating to important risks and uncertainties that could materially adversely affect the Companys business, financial condition or operating results. Those risk factors continue to be relevant to an understanding of the Companys business, financial condition and operating results.
Certain of those risk factors have been updated in this Form 10-Q to provide updated information, as set forth below. References to we, our and us in these risk factors refer to the Company.
Changes in government reimbursement levels could adversely affect our net sales, cash flows and profitability.
We derived 41.3% and 40.6% of our net sales for the six months ended June 30, 2012 and 2011, respectively, from reimbursements for O&P services and products from programs administered by Medicare, Medicaid and the U.S. Department of Veterans Affairs. Each of these programs set maximum reimbursement levels for O&P services and products. If these agencies reduce reimbursement levels for O&P services and products in the future, our net sales could substantially decline. In addition, the percentage of our net sales derived from these sources may increase as the portion of the U.S. population over age 65 continues to grow, making us more vulnerable to maximum reimbursement level reductions by these organizations. Reduced government reimbursement levels could result in reduced private payor reimbursement levels because fee schedules of certain third-party payors are indexed to Medicare. Furthermore, the healthcare industry is experiencing a trend towards cost containment as government and other third-party payors seek to impose lower reimbursement rates and negotiate reduced contract rates with service providers. This trend could adversely affect our net sales. For example, a number of states have reduced their Medicaid reimbursement rates for O&P services and products, or have reduced Medicaid eligibility, and others are in the process of reviewing Medicaid reimbursement policies generally, including for prosthetic and orthotic devices. Additionally, Medicare provides for reimbursement for O&P products and services based on prices set forth in fee schedules for ten regional service areas. Medicare prices are adjusted each year based on the Consumer Price IndexUrban (CPIU) unless Congress acts to change or eliminate the adjustment. The Medicare price (decreases)/increases for 2012, 2011, 2010, 2009, and 2008 were 2.4%, (0.1%), 0.0%, 5.0%, and 2.7% respectively. The Patient Protection and Affordable Care Act, Pub. L. No. 111-148, March 23, 2010 (PPACA) changed the Medicare inflation factors applicable to O&P (and other) suppliers. The annual updates for years subsequent to 2011 are based on the percentage increase in the CPI-U for the 12-month period ending with June of the previous year. Section 3401(m) of PPACA required that for 2011 and each subsequent year, the fee schedule update factor based on the CPI-U for the 12-month period ending with June of the previous year is to be adjusted by the annual economy-wide private nonfarm business multifactory productivity (the MFP Adjustment). The MFP Adjustment may result in that percentage increase being less than zero for a year and may result in payment rates for a year being less than such payment rates for the preceding year. CMS has not yet issued a final rule implementing these adjustments for years beyond 2011, but has indicated in a proposed rule that it will do so as part of the annual program instructions to the O&P fee schedule updates. See 75 Fed. Reg. 40040, 40122, et seq. (July 13, 2010). If the U.S. Congress were to legislate additional modifications to the Medicare fee schedules, our net sales from Medicare and other payors could be adversely and materially affected.
We cannot predict whether any such modifications to the fee schedules will be enacted or what the final form of any modifications might be.
Our substantial indebtedness could impair our financial condition and our ability to fulfill our obligations under our indebtedness.
We have substantial debt. As of June 30, 2012, we had approximately $504.4 million of total indebtedness and $99.5 million available under our Revolving Credit Facility.
The level of our indebtedness could have important consequences to us. For example, our substantial indebtedness could:
· make it more difficult for us to satisfy our obligations;
· increase our vulnerability to adverse general economic and industry conditions;
· require us to dedicate a substantial portion of our cash flow from operations to payments on our debt, thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate requirements;
· limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;
· place us at a competitive disadvantage compared to our competitors that have proportionately less debt;
· make it more difficult for us to borrow money for working capital, capital expenditures, acquisitions or other purposes;
· limit our ability to refinance indebtedness, or the associated costs may increase; and
· expose us to the risk of increased interest rates with respect to that portion of our debt that has a variable rate of interest.
(a) Exhibits. The following exhibits are filed herewith:
Exhibit No. |
|
Document |
|
|
|
3.1 |
|
Composite of Amended and Restated Certificate of Incorporation of Hanger, Inc., as amended through June 8, 2012. (Incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on June 8, 2012). |
|
|
|
10.1 |
|
Agreement and General Release, dated May 21, 2012, by and between Thomas F. Kirk and Hanger Prosthetics & Orthotics, Inc. (Incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on May 21, 2012). |
|
|
|
31.1 |
|
Written Statement of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
31.2 |
|
Written Statement of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
32 |
|
Written Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
101 |
|
The following financial information from the Companys Quarterly Report on Form 10-Q, for the period ended June 30, 2012, formatted in eXtensible Business Reporting Language: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows, (iv) Notes to Consolidated Financial Statements (1) |
(1) Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
HANGER, INC. |
|
|
|
|
Dated: August 3, 2012 |
/s/Vinit Asar |
|
Vinit Asar |
|
President and Chief Executive Officer |
|
(Principal Executive Officer) |
|
|
|
|
Dated: August 3, 2012 |
/s/George E. McHenry |
|
George E. McHenry |
|
Executive Vice President and Chief Financial Officer |
|
(Principal Financial Officer) |
|
|
|
|
Dated: August 3, 2012 |
/s/Thomas C. Hofmeister |
|
Thomas C. Hofmeister |
|
Vice President of Finance |
|
(Chief Accounting Officer) |